First Presentation of Parkinson Disease Patients to Neurologist
In this study information is gathered about the treatment of Parkinson patients who present themselves in a neurological practice for the first time
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||CEE PMSS (Central Eastern European Post-Marketing Surveillance Study) First Presentation of Mirapexin in Parkinson Patients|
- Number of De-novo Patients in Whom Monotherapy With Mirapexin® Could be Successfully Initiated [ Time Frame: 4 - 8 weeks ]
Clinical assessment of efficacy rated on the scale of 1 very good; 2 good; 3 moderate; 4 poor.
Number of participants rated with 1 or 2 (at least as "good")
- Change From Baseline in UPDRS (Unified Parkinson's Disease Rating Scale) Part I [ Time Frame: Baseline and 4 to 8 weeks ]Change in UPDRS Part I score from baseline to final visit. The score ranging from 0-16 (0= no disability, 16= maximum disability)
- Change From Baseline in UPDRS Part III [ Time Frame: Baseline and 4 - 8 weeks ]Change in UPDRS Part III score from baseline to final visit. Score ranging from 0 - 108 (0= no disability, 108 = worst disability).
- Global Clinical Assessments of Efficacy of Mirapexin® for All Patients [ Time Frame: 4 - 8 weeks ]
Global Clinical Assessment using the following scale: 1 very good; 2 good; 3 moderate; 4 poor efficacy.
The patients have been placed into categories according to the points on a scale.
|Study Start Date:||February 2006|
|Primary Completion Date:||September 2007 (Final data collection date for primary outcome measure)|
Show 311 Study Locations
|Study Chair:||Boehringer Ingelheim||Boehringer Ingelheim Pharmaceuticals|